Oncology Analyst II
+4 year(s) experience
Zachary McLellan is an Oncology analyst specializing in the coverage of prostate, ovarian, and breast cancers. He focuses on current market developments and treatment trends, as well as indication-specific market and drug forecasting. As an Analyst, Zachary shares his insights through individualized reports, direct client interactions, and Datamonitor Healthcare's online platform. He has also represented Datamonitor Healthcare at the 2016 ASCO conference. His conference coverage included timely analysis through bespoke reports and a live webinar that was attended by clients, prospective clients, investors and other interested parties.
Zachary joined Informa in June 2015 while completing an MSc in Biotechnology and Entrepreneurship from New York University. Prior to Informa, he worked as a chemist.
Zachary Writes For
By Zachary McLellan 22 Aug 2018
Zach McLellan, Jack Allen, and guest analyst Cameron Findlater discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of AndexXa for reversal of Eliquis and Xarelto & Eli Lilly's acquisition of ARMO Biosciences.
By Zachary McLellan 29 May 2018
Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of Sun Pharma's Yonsa in prostate cancer, and broad market commentary on Tesaro, Gilead, Clovis, Portola, BMS and Celgene
Topic Company analysis
By Zachary McLellan 15 May 2018
Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including a recap of the 2018 BIO CEO conference, Phase IIb results of aramchol in HIV-lipodystrophy NAFLD or NASH patients, and the approval of Ereleada (apalutamide) in non-metastatic castration-resistant prostate cancer.
By Zachary McLellan 10 Mar 2017
Perjeta (pertuzumab; Genentech/Roche/Chugai) is poised for a label expansion into the early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer setting after a positive readout from the Phase III APHINITY trial (ClinicalTrials.gov identifier: NCT01358877). In the trial, the combination of Perjeta, Herceptin (trastuzumab; Roche/Chugai), and chemotherapy showed a statistically significant improvement in invasive disease-free survival (iDFS) over Herceptin and chemotherapy alone for the adjuvant treatment of early-stage HER2+ breast cancer patients (Roche press release, 2017). This significant improvement in survival will likely mean the Perjeta/Herceptin/chemotherapy combination will be considered the new standard of care for early-stage HER2+ breast cancer patients receiving surgery
By Zachary McLellan 02 Jul 2015
On 29 June 2015, Celgene and Juno Therapeutics announced a global collaboration for the development and commercialization of chimeric antigen receptor T cells (CAR-T) and T-cell receptor
Topic Cell and gene therapy